Human PDE2A1 (GenBank Accession No. NM_002599), full length, with N-terminal GST-tag and N-terminal thrombin cleavage site, MW=132 kDa, expressed in a Baculovirus infected Sf9 cell expression system.

O00408

PDE2A, phosphodiesterase 2A

≥ 3442 pmol/min/µg

One unit is defined as the amount of enzyme that will convert 1 pmole of 3', 5'-cAMP to 5'-AMP per minute at 37°C.

Assayed using BPS's PDE2A Assay Kit, Cat. # 60320. Assay conditions: 10 mM Tris-HCl, pH 7.4, 10 mM MgCl₂, 0.1 mg/ml BSA, 0.05% Tween-20, 200 µM cAMP, 2.5 kU 5'-nucleotidase, and serial dilutions of PDE2A at 37°C for 20 min. Quantified by 5'- nucleotidase cleaving the 5' -AMP product and releasing the phosphate group which is detected by Malachite Green Reagent.

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 3 mM DTT, 20% glycerol, and 16 mM glutathione

Aqueous buffer solution

>6 months at -80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Seybold, J., et al., Blood 105 (9), 3569- 3576 (2005).
2. Martinez, S.E., et al., Proc. Natl. Acad. Sci. U.S.A. 99 (20), 13260-13265 (2002).

Application Reference(s):
1. Design and optimization of purine derivatives as in vivo active PDE10A inhibitors (2017)
2. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631 (2017)
3. Active Site Coupling in PDE:PKA Complexes Promotes Resetting of Mammalian cAMP Signaling (2014)

Avoid freeze/thaw cycles.

PDE

Recombinant Protein